Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Gastroenterology  |  Oncology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location
Clear Trial Filters

Abdominal Cancer Clinical Trials

A listing of Abdominal Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.


Found (5) clinical trials

Trial of Nab-paclitaxel in Patients With Desmoid Tumors and Multiply Relapsed/Refractory Desmoplastic Small Round Cell Tumors and Ewing Sarcoma

A two-cohort, fase II, open-label, non-randomized, multicenter clinical trial. 14 sites in Spain. Cohort 1: Subjects with desmoid tumor (DT) Cohort 2: Subjects with desmoplastic small round cell tumor or Ewing sarcoma (DSRCT and ES) Nab-paclitaxel (ABRAXANE) will be administered as follows: Age 21 and 80 years: 125 mg/m2 days ...


Intrathecal Dexmedetomidine Versus Fentanyl With Bupivacaine in Children Undergoing Major Abdominal Cancer Surgery

After obtaining approval of the local ethics committee of South Egypt Cancer Institute, Assiut University, Assiut, Egypt, and parent's written informed consent, a randomized double -blinded prospective study will be conducted on (60) pediatric patients. After applying standard monitors; Pulse oximetry (Spo2), Noninvasive arterial blood pressure, Electrocardiography (ECG), pre-medication with ...


Study of Efficacy and Safety of Laparoscopic Intra-abdominal Chemotherapy (PIPAC) Performed in Patients With Peritoneal Carcinomatosis From Colorectal Ovarian Gastric Cancer and Primary Peritoneal Tumors

Single center, open label, non-randomized, single-arm, repeated single dose study to explore the efficacy, safety, and Overall Response Rate (ORR) of cisplatin, oxaliplatin and doxorubicin when given as a pressurized intraperitoneal chemotherapy (PIPAC) to patients (men and women) with peritoneal carcinomatosis from ovarian, gastric and colorectal cancers and in primary ...


Daily Online Adaptation Versus Localization for MRI-Guided SBRT for Unresectable Primary or Oligometastatic Abdominal Malignancies

In light of this new technology and preliminary findings of low toxicity of online, adaptive, magnetic resonance (M)-guided stereotactic radiation on a single arm prospective study, the investigators propose to compare this technique to online MR-guided stereotactic body radiation therapy (SBRT) without adaptation. Online plan adaptation increases treatment times for ...


A clinical trial to evaluate treatments for patients with Thyroid Adenoma, Testicular Non-Seminomatous Germ Cell Tumor, Malignant Odontogenic Neoplasm, Primary Peritoneal High Grade Serous Adenocarcinoma, Bladder Adenocarcinoma, Ovarian Transitional Cell Carcinoma, Gastric Squamous Cell Carcinoma, Transitional cell carcinoma, Urethral Adenocarcinoma, Mucinous Adenocarcinoma, Nasal Cavity Adenocarcinoma, Paranasal Sinus Adenocarcinoma, Chordoma, Appendix Mucinous Adenocarcinoma, Anal Canal Neuroendocrine Carcinoma, Lung Carcinoid Tumor, Metaplastic Breast Carcinoma, Adrenocortical carcinoma, Mucinous cystadenocarcinoma, Bartholin Gland Transitional Cell Carcinoma, Major Salivary Gland Carcinoma, Extrahepatic Bile Duct Carcinoma, Adenoid Cystic Carcinoma, Vaginal Squamous Cell Carcinoma, Not Otherwise Specified, Nasopharyngeal Papillary Adenocarcinoma, Ovarian Germ Cell Tumor, Ovarian Mucinous Adenocarcinoma, Ureter Squamous Cell Carcinoma, Vulvar Squamous Cell Carcinoma, Placental site trophoblastic tumor, Vulvar Adenocarcinoma, Parathyroid Adenoma, Ovarian Adenocarcinoma, Esophageal Neuroendocrine Carcinoma, Rare Diseases, Paraganglioma, Pheochromocytoma, Endometrial Transitional Cell Carcinoma, Seminoma, Undifferentiated Gastric Carcinoma, Vaginal Adenocarcinoma, Small Intestinal Adenocarcinoma, Small Intestinal Squamous Cell Carcinoma, Acinar Cell Carcinoma, Pseudomyxoma Peritonei, Mesodermal mixed tumor, Islet cell carcinoma, Serous cystadenocarcinoma, Minimally Invasive Lung Adenocarcinoma, Fallopian Tube Adenocarcinoma, Ureter Adenocarcinoma, Nasopharyngeal Cancer, Intestinal Neuroendocrine Carcinoma, Intrahepatic Cholangiocarcinoma, Spindle Cell Neoplasm, Colorectal Squamous Cell Carcinoma, Endometrioid carcinoma, Cervical Adenocarcinoma, Malignant Testicular Sex Cord-Stromal Tumor, Esophageal Undifferentiated Carcinoma, Paranasal Sinus Cancer, Placental Choriocarcinoma, Pituitary Adenoma, Aggressive fibromatosis, Fibromyxoid Tumor, Teratoma With Malignant Transformation, Vulvar Carcinoma, Ovarian Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Penis, Urethral Squamous Cell Carcinoma, Fallopian Tube Transitional Cell Carcinoma, Cholangiocarcinoma, Scrotal Squamous Cell Carcinoma, Seminal Vesicle Adenocarcinoma, Pancreatic Acinar Cell Carcinoma, Nasopharyngeal Undifferentiated Carcinoma, Giant cell carcinoma, Dermoid Cyst, Gastric Neuroendocrine Carcinoma, Tracheal Carcinoma, Oral Cavity Carcinoma, Nerve Sheath Tumors, Lung Sarcomatoid Carcinoma, Nasal Cavity Carcinoma, Neoplasms, Unknown Primary, Anal Canal Undifferentiated Carcinoma, gastrointestinal stromal tumor, Oropharyngeal Undifferentiated Carcinoma

PRIMARY OBJECTIVES: I. To evaluate the Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 overall response rate (ORR) in subsets of patients with advanced rare cancers treated with ipilimumab plus nivolumab combination immunotherapy. SECONDARY OBJECTIVES: I. To evaluate toxicities in each cohort. II. To estimate overall survival (OS), progression-free ...